Amplification of c‐<i>myc</i> and c‐<i>erb</i>B‐2 proto‐oncogenes in human solid tumors: Frequency and clinical significance

Gutman, Mordechai; Ravia, Yehoshua; Assaf, Dan; Yamamoto, Tadashi; Rozin, R; Shiloh, Yosef

doi:10.1002/ijc.2910440509

Cited by 34 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of these factors are considered to be bad prognostic indicators. According to other authors there was no correlation with tumour size (Gutman et al, 1989;Seshadri et al, 1989) and age at diagnosis (Zhou et al, 1987;Seshadri et al, 1989).…”

mentioning

confidence: 89%

c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis

Schroeter

Potter²,

Rathsmann³

et al. 1992

Br J Cancer

View full text Add to dashboard Cite

SummaryIn a retrospective study the expression of the c-erbB-2 oncogene was determined immunohistochemically in 276 breast cancer samples from 253 patients with the antibody 21N. The follow-up period was between 7 and 12 years. This study showed a trend for an inverse relationship between c-erbB-2 positive tumours and estrogen receptors (ER). A correlation was assessed between c-erbB-2 positive tumours and histological grade, liver metastases as first site of metastases, disease free survival time (DFS) in the second and third year after diagnosis and overall survival time (OST) in the third and fourth year after diagnosis. A trend was seen between c-erbB-2 positive tumours and tumour size. No correlation was found between c-erbB-2 positive tumours and age at diagnosis. The method of operation and lymph node involvement. From this study we conclude that there is a significant difference in prognosis the first years after diagnosis, but this difference seems to vanish in a longer follow-up period of 12 years. This provides us with an explanation for the discrepancies in literature concerning c-erbB-2 expression and prognosis in breast cancer. Some investigators did not show differences in prognosis between positive and negative cases after a long follow-up period whereas investigations with a short term follow-up period up to 2-3 years have indeed established a more aggressive behaviour of c-erbB-2 overexpressionary tumours.

show abstract

mentioning

confidence: 89%

c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis

Schroeter

Potter²,

Rathsmann³

et al. 1992

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…A characteristic example is the alleged association between Myc amplification and poor prognosis, which is suggested by some studies, [39][40][41][42][43] but refuted by others. [44][45][46][47] Nevertheless, some expression profiling analyses 48 support a correlation between Myc levels and poor breast cancer outcome. In addition, an analytical approach integrating expression and copy number profiles 49,50 has indicated that the so-called "wound response" expression signature previously associated with poor overall survival and increased risk of metastasis in breast cancer 51 can be correlated with a coordi- nate amplification of Myc and Cops5 (a gene encoding one of the subunits of the Cop9 signalosome).…”

Section: Myc In Normal Human Breast and Breast Cancermentioning

confidence: 99%

Notch, Myc and Breast Cancer

Efstratiadis

Szabolcs²,

Klinakis³

2007

Cell Cycle

View full text Add to dashboard Cite

“…c-erbB-2 amplification and overexpression have been observed in several human tumors (18,19). In head and neck carcinomas, the frequencies of erbB-2 amplification and overexpression range from 0 to 41% (20)(21)(22).…”

Section: Genetic Alterations Oncogene Activationmentioning

confidence: 99%

Genetic alterations in head and neck squamous cell carcinomas

Nagai

1999

Braz J Med Biol Res

View full text Add to dashboard Cite

The genetic alterations observed in head and neck cancer are mainly due to oncogene activation (gain of function mutations) and tumor suppressor gene inactivation (loss of function mutations), leading to deregulation of cell proliferation and death. These genetic alterations include gene amplification and overexpression of oncogenes such as myc, erbB-2, EGFR and cyclinD1 and mutations, deletions and hypermethylation leading to p16 and TP53 tumor suppressor gene inactivation. In addition, loss of heterozygosity in several chromosomal regions is frequently observed, suggesting that other tumor suppressor genes not yet identified could be involved in the tumorigenic process of head and neck cancers. The exact temporal sequence of the genetic alterations during head and neck squamous cell carcinoma (HNSCC) development and progression has not yet been defined and their diagnostic or prognostic significance is controversial. Advances in the understanding of the molecular basis of head and neck cancer should help in the identification of new markers that could be used for the diagnosis, prognosis and treatment of the disease.

show abstract

Amplification of c‐myc and c‐erbB‐2 proto‐oncogenes in human solid tumors: Frequency and clinical significance

Cited by 34 publications

References 13 publications

c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis

c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis

Notch, Myc and Breast Cancer

Genetic alterations in head and neck squamous cell carcinomas

Contact Info

Product

Resources

About